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Agonistic antibodies against the Fas receptor, when
administered to mice in vivo, cause significant apoptosis
in the liver. In this study we show that anti-Fas antibody
not only causes apoptosis of liver cells but also provokes
hepatic inflammation. Two hours after injection of anti-
Fas, when mice displayed evidence of caspase-3 activa-
tion and apoptosis, we found significant hepatic induc-
tion of the CXC chemokines macrophage inflammatory
protein-2 and KC. Coincident with the chemokine induc-
tion was infiltration of the hepatic parenchyma by neu-
trophils. Neutralization experiments identified that
chemokines were the cause of Fas-induced hepatic in-
flammation, with KC having the predominant effect.
Chemokine induction in the livers of anti-Fas-treated
mice was not associated with activation of NF-B. In-
stead, it coincided with nuclear translocation of activa-
tor protein-1 (AP-1). AP-1 activation in liver was de-
tected 1–2 h after anti-Fas treatment, suggesting a
connection to the onset of apoptosis. When apoptosis
was prevented by pretreating mice with a caspase-3 in-
hibitor, AP-1 activation and hepatic chemokine produc-
tion were both significantly reduced. Hepatic inflamma-
tion was also reduced by 70%. Taken together, these
findings indicate that Fas ligation can induce inflamma-
tion in the liver in vivo. Inflammation does not arise
from Fas-mediated signaling through NF-B; rather, it
represents an indirect effect, requiring activation of
caspase-3 and nuclear translocation of AP-1.
Fas (CD95/Apo1) is a 43-kDa cell surface glycoprotein be-
longing to the tumor necrosis factor receptor family (1). Liga-
tion of the Fas receptor induces apoptosis by promoting pro-
teolytic cleavage of intracellular caspases (2). In vivo, Fas me-
diates apoptosis in numerous tissues (3, 4); the liver seems
especially sensitive, because systemic administration of agonis-
tic anti-Fas antibody to mice causes massive death of hepato-
cytes. Animals treated with anti-Fas die within a few hours,
with evidence of gross hemorrhage into the liver parenchyma
(5).
Although engagement of Fas receptors typically results in
apoptosis, Fas can also stimulate intracellular signaling path-
ways that lead to different responses. For example, when ago-
nistic anti-Fas antibody is injected subcutaneously rather than
systemically into mice, a robust local inflammatory response
occurs (6). Similarly, when mouse peritoneum is inoculated
with cells that express Fas ligand, local inflammation ensues
(7). Some believe that Fas-induced inflammatory responses are
triggered when neutrophils are the targets of apoptosis. In the
peritoneum, for example, death of “sentinel” neutrophils can
provoke inflammation caused simply by the release of the
abundant cytokines within these cells (7). Another means by
which Fas might induce inflammation, however, is to actively
stimulate target cells to produce chemoattractants. This latter
mechanism has been demonstrated in cell culture, in which
many types of cells upon treatment with anti-Fas antibody
begin to secrete the neutrophil chemoattractant interleukin-8
(8–11).
Interleukin-8 is a member of the chemokine superfamily of
leukocyte chemoattractants. It belongs to the CXC subfamily of
chemokines, named for the relative positions of two conserved
cysteines near its N terminus (12). CXC chemokines are them-
selves separated into two groups, based on the presence or
absence of a glutamic acid-leucine-arginine (ELR) motif up-
stream of CXC. The ELR sequence predicts potent chemotactic
activity toward neutrophils (13). Among the ELR-containing
CXC chemokines are interleukin-8, macrophage inflammatory
protein-2 (MIP-2),1 and growth-regulated oncogenes-, -, and
-, as well as the rodent peptides cytokine-induced neutrophil
chemoattractant and KC (14). CXC chemokines play a key role
in neutrophilic inflammation in many organs in vivo (12).
These compounds are induced by oxidants and cytokines by
means of NF-B and AP-1 consensus sequences within their
promoter regions (15–17).
In many cells, ligation of the Fas receptor causes nuclear
translocation of NF-B (18, 19). Bronchiolar epithelial cells,
which produce interleukin-8 in response to Fas ligation, also
display Fas-mediated activation of NF-B (11). This suggests
that Fas may induce chemokine production by a mechanism
involving NF-B. Whether Fas signals chemokine production
and inflammation in normal tissues is unknown. The objective
of the current study was to determine whether Fas ligation
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induces neutrophilic inflammation of the liver and, if so,
whether the inflammation is attributable to local induction of
CXC chemokines. The results indicate that Fas causes hepatic
inflammation in a process involving up-regulation of CXC che-
mokines. Fas-mediated chemokine induction in liver is not
dependent on NF-B but is controlled instead through the
death pathway downstream of caspase-3.
EXPERIMENTAL PROCEDURES
Animals—Female Swiss-Webster mice (25–30 g of body weight) were
obtained from Charles River Laboratories (Hollister, CA). All proce-
dures were approved by the Committee on Animal Research at the
University of California, San Francisco, and followed guidelines set by
the American Veterinary Medical Association.
Induction of Apoptosis in Mice and Manipulation of Apoptotic/In-
flammatory Responses in Vivo—The mice were injected intraperitone-
ally with purified hamster anti-mouse Fas monoclonal antibody (clone
Jo2; Pharmingen, San Diego, CA). Five treatment groups received Jo2
in doses of 1, 2.5, 5, 10, and 50 g. The control mice were treated with
hamster nonimmune IgG (Pharmingen). Two hours after injection, the
mice were killed for collection of liver tissue. A portion of each mouse
liver was fixed in 10% buffered formalin and embedded in paraffin. The
remainder was snap frozen in liquid nitrogen-cooled isopentane and
stored at 80 °C until use.
For chemokine neutralization experiments, neutralizing monoclonal
antibodies to murine KC or MIP-2 (0.2 mg in 0.1 ml) (R & D Systems,
Minneapolis, MN), were injected intravenously into mice 15 min before
intraperitoneal injection of Jo2. The control animals received nonim-
mune murine IgG (0.2 mg in 0.1 ml) (Pharmingen). The mice were killed
2 h after Jo2 injection.
For caspase-3 inhibition experiments, benzyloxycarbonyl-Asp-Glu-
Val-Asp-fluoromethylketone (zDEVD-fmk, R&D Systems) was admin-
istered intraperitoneally to mice (0.5 mg in 0.1 ml of 1% Me2SO) 15 min
before Jo2. The control animals were injected with an equivalent dose of
an inactive inhibitor (zFA-fmk, R&D Systems). The mice were killed 2 h
after Jo2 injection.
Measurement of Caspase-3 Activity—The livers were homogenized in
a solution of 25 mM HEPES, 5 mM EDTA, 5 mM MgCl2, and 5 mM
dithiothreitol supplemented with protease inhibitors. Caspase-3 activ-
ity was quantitated fluorometrically using a substrate conjugated with
7-amino-4-methyl coumarin (CaspACE assay system; Promega Corp.,
Madison, WI). To verify the specificity of the reaction, enzyme activity
in each sample (90 g of total protein) was measured in the presence
and absence of the caspase-3 inhibitor Ac-DEVD-CHO. The results
were expressed as pmol of substrate cleaved per mg of liver protein.
Immunohistochemistry—7-m sections of frozen liver tissue were
fixed for 10 min in acetone. Endogenous peroxidase activity was
quenched with hydrogen peroxide. The sections were then incubated for
30 min with phosphate-buffered saline containing 1% BSA (PBS/BSA).
For identification of neutrophils, the sections were treated with rat
anti-mouse neutrophil antibody (Ly6G, Pharmingen) or an irrelevant
control antibody diluted 1:100 in PBS/BSA. After 1 h, the slides were
washed with PBS and treated with reagents to block nonspecific avidin-
biotin binding (blocking kit; Vector Laboratories, Burlingame, CA). The
sections were then incubated with biotinylated anti-rat IgG (Pharmin-
gen; 1:100) followed by avidin-biotin complex (Vectastain ABC kit;
Vector Laboratories). Bound antibody was detected with 3,3-diamino-
benzidine. The sections were counterstained with hematoxylin before
coverslipping. The neutrophils were quantitated by direct counting of
stained cells in 10 random high power (20) fields. For identification of
KC and MIP-2, the liver sections were fixed and pretreated as above
and then incubated with anti-chemokine antibody (goat anti-mouse KC,
R & D; goat anti-mouse MIP-2, R & D) or control antibody diluted 1:40
in PBS/BSA. After 1 h, the slides were washed and treated with horse-
radish peroxidase-conjugated anti-goat IgG (Santa Cruz Biotechnolo-
gies, Santa Cruz, CA). Bound antibody was detected with 3,3-diami-
nobenzidine, and the sections were counterstained with hematoxylin as
described above.
Assessment of Apoptosis by Terminal Deoxynucleotidyl Transferase-
mediated dUTP Nick End Labeling (TUNEL)—Formalin-fixed sections
of liver tissue (5-m) were deparaffinized in xylene and hydrated in
graded ethanols. The apoptotic cells were identified using the Dead-
End® in situ apoptosis peroxidase detection kit (Promega).
Quantitation of Chemokines in Liver Tissue—KC and MIP-2 were
measured in whole liver homogenates using commercial sandwich en-
zyme-linked immunosorbent assays (Quantikine; R & D Systems). The
raw data were normalized to total protein in the liver homogenates. The
protein was quantitated by Bradford assay (Bio-Rad).
In Situ Hybridization—KC mRNA was detected in liver tissue using
a homologous 200-bp cDNA sequence from the rat chemokine cytokine-
induced neutrophil chemoattractant (20). The cytokine-induced neutro-
phil chemoattractant cDNA, subcloned into pGEM-4Z (Promega), was
used as a template for transcription of single-stranded antisense and
sense RNA probes containing [-33P]UTP (PerkinElmer Life Sciences).
The labeled probes were applied to frozen sections of liver tissue as
previously described (21).
RNase Protection Assay—Total RNA was isolated from liver tissue
using TRI reagent (Molecular Research Center, Cincinnati, OH). KC,
MIP-2, L32, and glyceraldehyde-6-phosphate dehydrogenase mRNA
were measured in 20 g of total liver RNA using a Riboquant® multi-
probe set (Pharmingen) labeled with [-32P]UTP (Amersham Bio-
sciences). Protected mRNA fragments corresponding to the probes of
interest were separated through 5% polyacrylamide-urea. The dried
gels were applied to x-ray film (X-Omat AR-5; Eastman Kodak Co.).
Autoradiographic signals were quantitated by scanning densitometry
using NIH Image 1.61 software.
Electrophoretic Mobility Shift Assay—Nuclear extracts were pre-
pared from liver tissue in Dignam C buffer (22). Electrophoretic mobil-
ity shift assay was performed as previously described (23). Briefly,
NF-B and AP-1 oligonucleotides were labeled with -32P using T4
polynucleotide kinase and used as probes for nuclear protein binding.
Protein-DNA binding reactions were carried out for 20 min on ice using
30 g of nuclear extract and 20,000 cpm of probe.
RESULTS
Anti-Fas Antibody (Jo2) Induces Apoptosis and Hepatic Che-
mokine Production—When administered to Swiss-Webster
mice in vivo, the agonistic anti-Fas antibody Jo2 caused dose-
dependent apoptosis of liver cells. Mice receiving as little as 2.5
g of Jo2 (approximately 0.1 mg/kg of body weight) exhibited
apoptosis; this was demonstrated both by TUNEL staining and
activation of caspase-3 (Fig. 1). When the dose of Jo2 was
increased to 5 g (0.2 mg/kg), the amount of apoptosis rose
significantly. Apoptotic responses reached a maximum be-
tween 10 and 50 g of Jo2 (0.4–2.0 mg/kg) (Fig. 1).
Coincident with apoptosis, Jo2 induced hepatic expression of
mRNA encoding the CXC chemokines KC and MIP-2 (Fig. 2).
Substantial increases in chemokine gene expression were evi-
dent even in response to low doses of the agonistic anti-Fas
antibody (5 g). In situ hybridization experiments showed that
CXC chemokine mRNA was widely distributed in Jo2-treated
liver, suggesting expression by hepatocytes (Fig. 3b). This was
confirmed by immunohistochemistry (Fig. 3d). Accompanying
the induction of KC and MIP-2 mRNA in Jo2-treated mouse
liver was the production of KC and MIP-2 proteins (Fig. 4). KC
and MIP-2 were detected at high levels in liver homogenates
from mice receiving 5 g of Jo2. At higher doses of Jo2, hepatic
chemokine levels showed less induction; this was true despite
significant up-regulation of their respective mRNAs (Fig. 2).
The discrepancy between chemokine mRNA and protein levels
at high doses of Jo2 is unexplained. It could be due to impaired
protein translation (24) or accelerated protein degradation in
apoptotic cells.
Jo2-treated Mice Exhibit Hepatic Neutrophil Infiltration—To
explore the biological consequences of CXC chemokine induc-
tion in Jo2-treated mice, the livers were examined for evidence
of neutrophil infiltration. Neutrophils were detected in Jo2-
treated livers but not in livers from control mice (Fig. 5a).
Neutrophils were most abundant in mice treated with 5 g of
Jo2, the dose of antibody that caused the greatest induction of
KC and MIP-2 (Fig. 5b). 5 g of Jo2 caused a 10-fold increase in
hepatic neutrophils relative to controls. Overall, chemokine
production and neutrophilic inflammation varied in parallel
(Figs. 4 and 5). To determine which of the two chemokines is
the dominant neutrophil chemoattractant in Jo2-treated liver,
we performed experiments in which mice were injected with
neutralizing antibodies against KC or MIP-2 15 min before Jo2.
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Neither antibody influenced hepatic apoptosis (not shown).
Anti-KC abolished hepatic neutrophil recruitment following
Jo2 injection, but anti-MIP-2 had no effect on neutrophil accu-
mulation in the liver (Table I).
Jo2 Does Not Induce NF-B Activation in Liver but Promotes
AP-1 DNA Binding Activity—Because Fas can activate NF-B
(18, 19) and NF-B can in turn activate transcription of KC and
MIP-2 (15, 16), we investigated whether NF-B plays a role in
Jo2-mediated induction of hepatic chemokines. We performed
DNA binding experiments using nuclear extracts from mouse
liver harvested 30 min, 60 min, and 2 h after Jo2 injection
together with a consensus NF-B oligonucleotide (Fig. 6a). No
NF-B binding was observed at any time after Jo2 injection.
This was true despite strong NF-B binding activity in positive
control livers treated with lipopolysaccharide. As an alterna-
tive possibility, we considered that Jo2 might induce chemo-
kine expression in liver by stimulating AP-1. AP-1 binding
FIG. 1. Dose-dependent apoptosis in
mouse liver in response to anti-Fas.
The data depict apoptosis in mouse liver
2 h after Jo2 injection, as measured by
TUNEL staining and quantitative assay
of caspase-3 activity. a, photomicrographs
of TUNEL stains from mice that received
0, 2.5, or 5 g of Jo2 or 5 g of control IgG.
b, histogram showing the number of
TUNEL-positive cells per high power field
(HPF, 20) as a function of Jo2 dose. Con-
trols received 5 g of IgG. c, histogram
depicting caspase-3 activity in liver as a
function of Jo2 dose. Controls received 5
g of IgG. The values represent the
means  S.E. *, p  0.05; #, p  0.001
versus IgG control.
FIG. 2. Induction of CXC chemokine mRNA in mouse liver
after Jo2 injection. The autoradiogram depicts the expression of KC
and MIP-2 mRNA in mouse liver 2 h after injection of Jo2. Control
mRNA signals encoding L32 and glyceraldehyde-6-phosphate dehydro-
genase are at the bottom of the gel. Duplicate lanes represent samples
from two different mice that received either Jo2 at doses of 5, 10, or 50
g or 5 g of control IgG (CTRL). As little as 5 g of Jo2 (0.2 mg/kg)
caused substantial induction of both KC and MIP-2 mRNA in the liver.
Higher doses of Jo2 did not cause a progressive rise in KC or MIP-2
mRNA. FIG. 3. In situ hybridization and immunohistochemistry for
KC in mouse liver sections. Photomicrographs illustrate the local-
ization of KC in mouse liver by in situ hybridization (a–c) and immu-
nohistochemistry (d and e). Tissue was obtained 2 h after injection of
either 5 g of Jo2 or 5 g of control IgG. A control liver incubated with
a specific antisense KC cRNA probe (a) shows no hybridization signal.
A Jo2-treated liver incubated with an antisense KC probe (b) shows
diffuse KC transcripts throughout the parenchyma. A Jo2-treated liver
incubated with a sense KC probe as a control (c) shows no specific
hybridization signal. Anti-KC antibody identifies hepatocytes as the
source of KC in the liver of a Jo2-treated mouse (d). Immunoreactive KC
is not detectable in the liver of a control mouse (e). Similar data were
obtained for MIP-2 (not shown). Original magnification was 10 for a–c
and 20 for d and e.
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activity was first detected in nuclear extracts from mouse liver
1 h after Jo2 injection (Fig. 6b). AP-1 activation increased at
2 h. These results suggest that Jo2-mediated induction of he-
patic chemokines is dependent on AP-1 rather than NF-B.
Jo2 Mediates Hepatic Chemokine Expression and Neutrophil
Recruitment Downstream of Caspase-3 Activation—The rela-
tively late nuclear translocation of AP-1 in Jo2-treated livers
suggests that activation of this transcription factor is not a
direct consequence of Fas ligation. To determine whether
caspase activation is required, we treated mice with the
caspase-3 inhibitor zDEVD-fmk and monitored its effect on
AP-1 in response to Jo2. zDEVD-fmk reduced caspase-3 activ-
ity in Jo2-treated liver by 90% (Fig. 7, left panel). Inhibition of
caspase-3 was accompanied by elimination of Fas-mediated
AP-1 DNA binding activity (Fig. 8). It was also accompanied by
significant blunting of the Fas-mediated induction of KC and
MIP-2 in mouse liver (48 and 78%, respectively, p  0.05; Fig.
7, middle panel). Mice treated with zDEVD-fmk exhibited a
substantial reduction in the neutrophilic inflammatory re-
sponse to Jo2 (70%, p  0.01; Fig. 7, right panel). These results
indicate that caspase-3 is a critical mediator of hepatic inflam-
mation during apoptosis. They suggest that inflammation
arises from caspase-3-mediated activation of AP-1, which in-
duces chemokines that stimulate neutrophil recruitment to the
liver.
DISCUSSION
The current study shows that in Fas-mediated liver injury in
vivo, engagement of Fas receptors not only causes cell death
but also stimulates local production of proinflammatory che-
mokines. Chemokine production and cell death are activated in
parallel in response to anti-Fas, suggesting that the two proc-
esses are closely related. The chemokines induced in response
to Fas are biologically active; KC in particular causes active
recruitment of neutrophils to the hepatic parenchyma. To-
gether these findings indicate that in vivo, tissue inflammation
can result from what was once considered a pure apoptotic
stimulus.
Apoptosis has classically been viewed as a silent mode of cell
FIG. 4. KC and MIP-2 in mouse liver after Jo2 injection. Graph
depicts KC and MIP-2 proteins measured by enzyme-linked immu-
nosorbent assays in mouse liver homogenates 2 h after Jo2 injection.
Control mice received 5 g of IgG. KC and MIP-2 were maximally
induced at a dose of 5 g of Jo2. At higher doses, hepatic levels of both
chemokines diminished. The values represent the means  S.E. *, p 
0.05, versus IgG control.
FIG. 5. Neutrophilic inflammation of Jo2-treated livers. a, pho-
tomicrographs depict immunoreactivity for neutrophils in mouse liver
after injection with control IgG or Jo2. No neutrophils were detected in
control mice, but abundant cells were identified in Jo2-treated liver
with a diffuse distribution throughout the hepatic lobule. b, graph
depicts the results of direct neutrophil counts in Jo2-treated livers.
Neutrophils were most abundant in mice that received 5 g of Jo2. The
values represent the means  S.E. *, p  0.05, versus IgG control.
TABLE I
Hepatic inflammation in Jo2-treated liver is reduced by anti-
chemokine antibody
The values depict neutrophil counts/high power field in mouse liver
2 h after Jo2 injection. 15 min before Jo2 injection, mice were pretreated
with 0.2 mg of neutralizing anti-chemokine antibody (anti-KC or anti-
MIP-2) or an isotype-matched control IgG. Neutrophil infiltration was
significantly reduced by anti-KC (75%; p  0.01). Anti-MIP-2 caused
a modest but insignificant reduction in neutrophil recruitment to the
liver. The values represent the means  S.E.
Treatment Neutrophils/HPF
Jo2  anti-KC 3.56  0.8a
Jo2  control IgG 13.8  3.4
Jo2  anti-MIP-2 5.2  2.4
Jo2  control IgG 9.6  4.1
a p  0.01 versus control IgG.
FIG. 6. Electrophoretic mobility shift assay of liver nuclear
extracts after treatment with Jo2. Autoradiograms depict DNA
binding of nuclear extracts from Jo2- or IgG-treated mouse livers to an
NF-B (a) or AP-1 (b) consensus oligonucleotide. Panel a shows no
activation of NF-B in Jo2-treated liver, at any time from 30 min to 2 h
after injection. Lipopolysaccharide-treated mouse liver (LPS) serves as
a positive control. The negative control represents lipopolysaccharide-
treated liver incubated with labeled probe in the presence of a 200-fold
excess of unlabeled competitor (Comp). Panel b shows that AP-1 DNA
binding activity becomes detectable at 1 h after Jo2. AP-1 binding is
increased at 2 h.
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death, in which affected cells are cleared by their neighbors or
professional phagocytes without eliciting an inflammatory re-
sponse (25–27). Apoptotic cells are recognized by cell surface
display of compounds such as long chain carbohydrates, throm-
bospondin, or anionic phospholipids, which interact with recep-
tors on phagocytic cells in a manner that avoids induction of
proinflammatory cytokines (28, 29). However, despite the
mechanisms that have evolved for inconspicuous removal of
apoptotic cells, recent studies indicate that phagocytes can
produce inflammatory cytokines upon ingestion of apoptotic
bodies (30). In addition, apoptotic cells themselves are capable
of producing cytokines. Cells from colon (8), synovium (9), brain
(10), and lung (11) have each been reported to produce CXC
chemokines upon exposure to Fas agonists or tumor necrosis
factor in culture. Their ability to provoke inflammation in vivo,
however, has not been demonstrated. Our study shows that in
the intact liver, anti-Fas stimulates hepatocytes to produce
chemokines, which in turn results in hepatic inflammation.
Connections between apoptosis and inflammation in vivo are
being recognized with increasing frequency. For example, clas-
sical inflammatory stimuli such as ischemia reperfusion (31,
32), galactosamine-endotoxin (33), and bleomycin (34) typically
cause apoptosis before the onset of leukocyte infiltration. When
apoptosis is inhibited in these experimental models, the leuko-
cyte response disappears; this suggests that programmed cell
death plays an essential role in the completion of the inflam-
matory response. On the other hand, the concept that apoptotic
agents can induce tissue inflammation by themselves, in the
absence of independent inflammatory signals, has not been
extensively explored (35, 36). One group recently reported that
smooth muscle cells in the carotid artery, triggered to undergo
apoptosis by activation of the Fas-associated death domain,
produced CXC chemokines, and elicited an inflammatory re-
sponse in the vessel wall (36). We provide evidence that similar
events occur in the liver in response to an agonistic anti-Fas
antibody and define the pathway that leads from Fas through
chemokines to inflammation.
Fas ligation caused simultaneous induction of MIP-2 and KC
in mouse liver. This is in keeping with the common modes of
gene regulation within the CXC chemokine subfamily (15–17).
Recruitment of neutrophils to the liver, however, was attribut-
able primarily to KC alone. Why KC would be preeminent in
eliciting a neutrophil response is uncertain, given that both KC
and MIP-2 interact with the same receptor (CXCR2) on murine
neutrophils (37). There is some evidence that KC and MIP-2
differ as neutrophil chemoattractants in vivo (38, 39). For ex-
ample, although KC and MIP-2 are both induced in the lung in
response to Nocardia asteroides infection (40) and bleomycin
treatment (41), neutralizing antibodies against MIP-2 have
little effect on tissue inflammation. This parallels exactly what
we found with MIP-2 neutralization in liver. In our study,
neutralizing antibodies against KC abrogated the inflamma-
tory response to Fas ligation. Thus, KC represents the primary
neutrophil chemoattractant mediating Fas-induced hepatic
inflammation.
In our experiments, anti-Fas-induced hepatic chemokine
production is independent of NF-B. Although in some cells
Fas is believed to stimulate chemokine secretion by activating
NF-B (11), this appears not to be the principal pathway to
Fas-induced chemokine production by hepatocytes. In cultured
hepatocytes, anti-Fas antibody is capable of activating NF-B
(42); in the liver in vivo, however, anti-Fas induces only modest
nuclear translocation of NF-B, even at lethal doses (43). Our
experiments employed a relatively low dose of anti-Fas anti-
body. Thus, the likelihood of activating NF-B in hepatocytes
was low. More importantly, at doses of anti-Fas that caused
maximal hepatic chemokine induction, NF-B DNA binding
was minimal or absent.
Fas-induced chemokine production in the liver did coincide
with nuclear translocation of AP-1. AP-1 was activated rela-
tively late after Jo2 treatment, suggesting that it was not a
direct consequence of Fas ligation as reported in some cells (44,
45). The time course suggested instead that AP-1 was activated
in dying cells as part of a stress response (46). In the intact
liver, Fas induced CXC chemokines and neutrophilic inflam-
mation only after activation of caspase-3. Although this is at
odds with cell culture data that Fas induces chemokines inde-
pendently of apoptosis (9, 36), it is consistent with several
reports in vivo that caspase inhibition prevents inflammation
as well as cell death (31, 32, 34, 47).
Interestingly, despite numerous studies investigating Fas-
mediated apoptosis in liver, hepatic inflammation has not pre-
viously been recognized (5, 33). The explanation for this may lie
in the fact that chemokine induction in response to Fas appears
dose-dependent (Fig. 4). At very low doses of anti-Fas, there is
probably too little apoptosis to induce hepatic chemokines; at
high doses, apoptosis is massive but there is no inflammation,
perhaps because of a caspase-3-dependent block in chemokine
translation (24). Only at moderate doses of anti-Fas does apo-
ptosis stimulate an inflammatory response (Fig. 5). This inter-
mediate situation may be most relevant to organ injury in vivo,
in which moderate levels of apoptosis can continue over pro-
longed intervals. In this scenario, ongoing apoptosis could be an
FIG. 7. Caspase-3 inhibition reduces chemokine induction and
neutrophilic infiltration in Jo2-treated liver. Graphs depict
caspase-3 activity (left panel), KC and MIP-2 (middle panel), and neu-
trophil counts (right panel) in mouse liver 2 h after Jo2, following
pretreatment with either the caspase-3 inhibitor zDEVD or the control
compound zFA. zDEVD markedly reduced caspase-3 activation in re-
sponse to Jo2. ZDEVD also significantly impaired the hepatic induction
of KC (58%) and MIP-2 (78%). These events were accompanied by
reduced neutrophil recruitment to the hepatic parenchyma (70%).
The values represent the means  S.E. *, p  0.05; #, p  0.01, versus
zFA.
FIG. 8. Inhibition of caspase-3 eliminates AP-1 DNA binding
activity in the livers of Jo2-treated mice. Autoradiogram illus-
trates AP-1 activation in the livers of mice pretreated with either the
caspase-3 inhibitor zDEVD or the control inhibitor zFA prior to Jo2
injection. Mice pretreated with zFA exhibit AP-1 DNA binding activity
at 2 h after Jo2. By contrast, mice pretreated with zDEVD exhibit no
AP-1 DNA binding at 2 h. No DNA binding is observed in nuclear
extracts incubated with a 200-fold excess of cold competitor (Comp).
Each lane represents the liver nuclear extract from a separate mouse.
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essential component of a chronic inflammatory response.
In summary, the current experiments demonstrate that Fas
ligation induces hepatic chemokine expression, which in turn
causes neutrophilic inflammation of the liver. Chemokines and
inflammation are not induced directly by Fas but instead are
consequences of caspase-3 activation. The results suggest that
CXC chemokines are induced as part of a stress response to cell
death, which involves nuclear translocation of AP-1. An impor-
tant consequence is neutrophil recruitment, which can poten-
tiate organ injury by release of oxidants and proteinases (48).
To the extent that inflammation represents a maladaptive
response to apoptosis, inhibition of apoptosis holds promise as
a strategy to limit inflammatory responses. Indeed, caspase
inhibitors may have broad clinical utility as modulators of both
acute and chronic inflammatory diseases.
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